HF Sinclair Corporation Form 8-K Summary
Business Context and Reporting Period
HF Sinclair Corporation filed a Form 8-K on July 5, 2022, reporting an event effective July 2, 2022. The filing concerns board composition and does not report quarterly or annual financial results.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other financial performance metrics.
Material Changes
- The Board expanded from eleven to twelve members.
- Rhoman J. Hardy was appointed as an independent director effective July 2, 2022.
- The Board determined that Mr. Hardy satisfies the independence requirements of the New York Stock Exchange listing rules and Exchange Act Rule 10A-3.
Management Commentary, Risks, and Unusual Items
Mr. Hardy retired from Shell USA, Inc. in 2022 after more than 34 years in the oil and gas industry, most recently serving as Senior Vice President, Shell Chemicals and Products, for the U.S. Gulf Coast. The Company cited his energy infrastructure, technical, operational, executive, and general management experience as relevant to Board service.
Mr. Hardy will receive the standard non-management director compensation described in the Company’s 2022 proxy statement and will enter into the Company’s standard indemnification agreement. The filing states that there were no arrangements or understandings relating to his selection, no relevant family relationships, and no transactions requiring disclosure under Item 404(a) of Regulation S-K.
The filing provides no financial guidance, operating outlook, contingencies, or material risk updates.
Important Facts to Verify
- Confirm the effective date of Mr. Hardy’s appointment and the Board’s increase to twelve members.
- Review the Company’s 2022 proxy statement for the applicable director compensation arrangements.
- Assess any subsequent filings for changes to Board composition, committee assignments, or director independence.
- Note that the press release furnished as Exhibit 99.1 under Regulation FD is not deemed filed for Section 18 liability purposes unless specifically incorporated by reference.